Country

INFOGRAPHIC: XEOMIN® (incobotulinumtoxinA) PEDIATRIC CHRONIC SIALORRHEA

 

XEOMIN® (incobotulinumtoxinA) is now approved by the FDA for the treatment of patients aged 2 years and older with chronic sialorrhea, or drooling. XEOMIN is the first and only FDA-approved neuromodulator with this indication. You can read the full announcement here.

View our animated infographic detailing our latest approval by clicking the image below:

For a downloadable PDF version, click here.

 

Press Contact

Jane Yarbrough
Corporate Communications
Merz Therapeutics
Merz Pharmaceuticals, LLC
6601 Six Forks Road, Suite 430
Raleigh, NC 27615

 

(984) 218-0983
Jane.Yarbrough@merz.com


Merz Therapeutics

At Merz Therapeutics, we seek to address the unique needs of people who suffer from movement disorders, neurological conditions, and other health conditions that severely impact patients’ quality of life. With our patient-centric approach, cutting-edge research and development efforts, highly-scientific medical affairs resources and dedicated commercial teams, we continue the advancement of new and individualized treatment standards, including botulinum toxin. Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is headquartered in Frankfurt, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Pharmaceuticals GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that serve unmet patient and customer needs.